New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

The H5N1 avian flu is circulating in cows and other mammals. Whether it will make a permanent leap to humans is another question ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

The US Department of Health and Human Services is weighing whether to fund new Marburg and Sudan Ebola virus vaccines even as Secretary Robert F. Kennedy Jr. overhauls the US immunization landscape, ...

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.